Skip to content

Genetics

The State of the Art of Glaucoma Genetics

Glaucoma Genetics: State of the Science

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs, MD, PhD, said in an update on glaucoma genetics in her keynote at the Glaucoma Research Foundation’s 2019 Glaucoma 360 New Horizons Forum here. The goal of glaucoma genetics research,…

Read More

After XLRS Gene Therapy Disappoints, AGTC Looks to ‘Transformative Year’

Can 2019 Be ‘Transformative’ for AGTC?

Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied Genetic Technologies Corporation (AGTC) is seeking a path forward to develop the rest of its ophthalmology portfolio on its own. President and CEO Sue Washer tells OIS Weekly that 2019…

Read More

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD Dr. Ahmed has been a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in innovative glaucoma surgery includes coining the term microinvasive glaucoma surgery…

Read More

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies are also making moves, as evidenced by Astellas Pharma’s acquisition last week of Quethera, which is pursuing a novel gene therapy program for treatment of glaucoma. This week, we look…

Read More

Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an inherited retinal disorder, it was the latest move into genetic medicine by big ophthalmology players. Already, Novartis had made two significant moves in the gene therapy space, and Roche expanded…

Read More

Eye Care Plays Big at Gene and Cell Meeting

Eye Care Plays Big at Gene and Cell Meeting

Eye care commanded a key stage at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) last week in Chicago. In all, 53 abstracts in retina were presented, but there were also presentations in glaucoma, corneal clouding, and even an ocular muscular disorder. Here are four presentations by companies in…

Read More

15 Things We Learned at OIS@ASCRS

Takeaways from OIS@ASCRS 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision accommodating intraocular lens implanted. The average objective accommodation at six months measured 2.00 diopters, he said. For the first time, Keranova presented preclinical results of its all-in-one cataract surgery platform.…

Read More

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on public market activity and “Masters of the Industry,” and a new panel on frontiers in femtosecond lasers. It’s all set for next Thursday, April…

Read More

MeiraGTx Gene Therapy Candidate for Achromatopsia Moves Forward

Emerging Gene Therapy Candidate Advances

An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for A002, which is for the treatment of achromatopsia (ACHM) due to mutations in the CNGB3 gene. A few weeks earlier,…

Read More

Handicapping the Entries in the Geographic Atrophy Space

Handicapping the Entries in the Geographic Atrophy Space

The race to find an effective treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) for which no approved treatment exists, has zeroed in on the complement pathway – and among the three lead candidates in this space, Apellis Pharmaceuticals’ APL-2 seems to have the early lead. Another lead contender, Ophthotech’s…

Read More

Can Ocular Therapies Diversify Biogen Portfolio?

Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus (AAV) gene delivery vectors, which have shown promise in early studies for treating a variety of retinal disorders. Biogen seems to be moving quickly into the ocular gene therapy arena.…

Read More
Scroll To Top